CytomX Therapeutics (CTMX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$18.3M

Revenue (quarter)

$1.4M

Revenue growth (year over year)

−92.40%

Gross profit (trailing twelve months)

$18.3M

Gross margin

100.00%

Net income (trailing twelve months)

−$79.7M

Net income (quarter)

−$20.7M

Net income growth (year over year)

−13319.48%

Net margin

−435.19%

Return on equity

−39.18%

EPS (trailing twelve months)

−$0.57

Book value per share

$1.39

P/E (trailing twelve months)

—

Price to book

1.68

Debt to assets

20.76%

Payout ratio

—

Dividend yield

—

Company profile

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

• Is CytomX Therapeutics (CTMX) profitable?

  No. CytomX Therapeutics reported a net loss of $79.7M over the trailing twelve months.

• How much revenue does CytomX Therapeutics (CTMX) make?

  CytomX Therapeutics generated $18.3M in revenue over the trailing twelve months, down 92.40% year over year.

• How do I buy stock in CytomX Therapeutics (CTMX)?

  CTMX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.